---
title: "Supernus and Indivior close merger and borrow $650 million to pay Indivior holders"
url: "https://aibio.space/news/supernus-indivior-close-merger-borrow-650-million-pay-indivior-holders/"
event_date: "2026-11-02"
date_published: "2026-11-05"
description: "The combined Supernus, Inc. took a Citibank-led secured term loan that, with cash on hand, funds a $1.0 billion special dividend to Indivior holders. Legacy Supernus stock is being delisted."
---

# Supernus and Indivior close merger and borrow $650 million to pay Indivior holders

On November 2, Supernus Pharmaceuticals and Indivior Pharmaceuticals (Nasdaq: INDV) completed their merger. The combined company, renamed Supernus, Inc. and led by President and CEO Jack Khattar, drew a $650,000,000 senior secured term loan from Citibank, N.A. Each Supernus share became 1.5401 Indivior shares. Legacy Indivior holders own approximately 56.5% of the company and former Supernus holders approximately 43.5%, on a fully diluted basis. The companies said they used the loan and existing cash to finance a $1.0 billion special dividend to Indivior's holders, so the combined company starts out borrowing to pay shareholders. The credit agreement also lets it use the money to refinance Supernus's UBS credit line and for general corporate purposes. Against that, Indivior reported third quarter net income of $137 million. [Merger 8-K](https://www.sec.gov/Archives/edgar/data/1625297/000110465926121013/tm2628720d1_8k.htm) · [Credit agreement](https://www.sec.gov/Archives/edgar/data/1625297/000110465926121013/tm2628720d1_ex10-1.htm) · [Merger release](https://www.sec.gov/Archives/edgar/data/1356576/000110465926121014/tm2628719d1_ex99-1.htm) · [Indivior Q3 results](https://www.sec.gov/Archives/edgar/data/1625297/000119312526436953/d169609dex991.htm)

This is not a bankruptcy or a default. Supernus Pharmaceuticals asked Nasdaq to suspend trading in its stock before the open on November 2 and to file a Form 25 to delist it, because it is now a wholly owned subsidiary; it then intends to file a Form 15 to end its reporting duties. The SUPN symbol moved to the renamed Indivior, which the companies said would begin trading under it on November 3 in place of INDV. [Supernus listing 8-K](https://www.sec.gov/Archives/edgar/data/1356576/000110465926121103/tm2628719d2_8k.htm) · [Supernus 8-K](https://www.sec.gov/Archives/edgar/data/1356576/000110465926121014/tm2628719d1_8k.htm)

## What the loan costs and what it demands

Until the month after its first quarterly statements are delivered, the loan bears interest at Term SOFR plus 2.25% or a base rate plus 1.25%. After that, the SOFR margin moves between 2.00% and 2.75% depending on total net leverage. The loan matures on the earlier of the fifth anniversary of the agreement's effective date and the date 91 days before the convertible notes mature. Quarterly principal payments start at $4,062,500 on March 31, 2027, rise to $8,125,000 in 2029 and reach $12,187,500 from March 31, 2031. [Merger 8-K](https://www.sec.gov/Archives/edgar/data/1625297/000110465926121013/tm2628720d1_8k.htm) · [Credit agreement](https://www.sec.gov/Archives/edgar/data/1625297/000110465926121013/tm2628720d1_ex10-1.htm)

The lenders hold a first priority lien on substantially all the borrower group's property, guaranteed by certain US and UK subsidiaries. Total net leverage may not exceed 3.25 to 1.00 for quarters ending before December 31, 2027, and 3.00 to 1.00 after that, and interest coverage must stay at or above 3.00 to 1.00. Citibank, N.A. is administrative agent. Citibank, N.A., Bank of America, N.A., PNC Capital Markets, LLC, Truist Securities, Inc. and U.S. Bank National Association are joint lead arrangers and joint bookrunners. [Credit agreement](https://www.sec.gov/Archives/edgar/data/1625297/000110465926121013/tm2628720d1_ex10-1.htm) · [Merger 8-K](https://www.sec.gov/Archives/edgar/data/1625297/000110465926121013/tm2628720d1_8k.htm)

The term loan sits on top of $500 million of 0.625% Convertible Senior Notes due 2031, which Indivior sold in March and partly used to repay its earlier $333 million term loan. Because of the special dividend, the conversion rate rose on November 3 from 24.0033 to 30.9355 shares per $1,000 of notes, a conversion price of approximately $32.33. The company said no bondholders converted. At September 30, after buybacks, Indivior reported a stockholders' deficit of $60 million. [Indivior 10-Q](https://www.sec.gov/Archives/edgar/data/1625297/000162828026068013/indv-20260930.htm) · [Conversion rate 8-K](https://www.sec.gov/Archives/edgar/data/1625297/000162529726000030/indv-20261103.htm)

## The businesses that must carry the debt

Indivior's third quarter revenue was $356 million, of which SUBLOCADE brought in $267 million; adjusted EBITDA was $211 million and cash and investments were $332 million. SUBLOCADE supplied $753 million of $1,016 million in nine-month revenue. Supernus reported third quarter revenue of $226.8 million, operating earnings of $21.2 million and cash, cash equivalents and current marketable securities of $359.5 million, but a nine-month operating loss of $45.1 million. Supernus said the combination is expected to realize $125 million in annual cost synergies, a target not yet demonstrated. [Indivior Q3 results](https://www.sec.gov/Archives/edgar/data/1625297/000119312526436953/d169609dex991.htm) · [Supernus Q3 results](https://www.sec.gov/Archives/edgar/data/1356576/000135657626000050/ex991earningsrelease.htm)

Indivior also carries the SUBOXONE Film dental litigation. As of October 23, about 1,925 cases naming about 22,098 plaintiffs sat in MDL No. 3092 in the Northern District of Ohio. The 10-Q says bellwether trials would not come before the end of the first quarter of 2028 and that no estimate of possible loss can be made. The merger release lists the new indebtedness and integration costs among its risks. [Indivior 10-Q](https://www.sec.gov/Archives/edgar/data/1625297/000162828026068013/indv-20260930.htm) · [Merger release](https://www.sec.gov/Archives/edgar/data/1356576/000110465926121014/tm2628719d1_ex99-1.htm)

## Who runs it and who advised

Timothy C. Dec is chief financial officer, and Tony Kingsley, a former Indivior director, chairs an eight-member board. Kingsley, Juliet Thompson, Keith Humphreys and Mark Stejbach came from Indivior; Khattar, Georges Gemayel, Carrolee Barlow and Bethany Sensenig came from Supernus. Indivior's CEO Joseph Ciaffoni, CFO Ryan Preblick, chief commercial officer Patrick Barry and chief legal officer Jeffrey Burris left. Ciaffoni receives $1,672,500 in salary continuation over 18 months, a further $1,672,500 payment and full vesting of his restricted stock units. [Merger 8-K](https://www.sec.gov/Archives/edgar/data/1625297/000110465926121013/tm2628720d1_8k.htm)

Cantor Fitzgerald & Co. was lead financial advisor to Supernus Pharmaceuticals, with Wells Fargo as an additional financial advisor, Saul Ewing LLP as legal counsel and Morgan Lewis UK on certain ex-US matters. Jefferies LLC and Piper Sandler & Co. were joint financial advisors to Indivior, Goodwin Procter LLP was its counsel and Citi also advised it. Neither company's standalone 2026 guidance still applies. The combined company says the acquired business's financial statements and pro forma figures will follow within 71 days. Until then, holders have no combined balance sheet showing net leverage against the 3.25 to 1.00 ceiling. [Merger release](https://www.sec.gov/Archives/edgar/data/1356576/000110465926121014/tm2628719d1_ex99-1.htm) · [Merger 8-K](https://www.sec.gov/Archives/edgar/data/1625297/000110465926121013/tm2628720d1_8k.htm) · [Supernus Q3 results](https://www.sec.gov/Archives/edgar/data/1356576/000135657626000050/ex991earningsrelease.htm)

Sources

- https://www.sec.gov/Archives/edgar/data/1356576/000110465926121014/tm2628719d1_ex99-1.htm
- https://www.sec.gov/Archives/edgar/data/1625297/000110465926121013/tm2628720d1_8k.htm
- https://www.sec.gov/Archives/edgar/data/1625297/000110465926121013/tm2628720d1_ex99-1.htm
- https://www.sec.gov/Archives/edgar/data/1625297/000162529726000030/indv-20261103.htm
- https://www.sec.gov/Archives/edgar/data/1356576/000110465926121014/tm2628719d1_8k.htm
- https://www.sec.gov/Archives/edgar/data/1356576/000110465926121103/tm2628719d2_8k.htm
- https://www.sec.gov/Archives/edgar/data/1625297/000110465926121013/tm2628720d1_ex10-1.htm
- https://www.sec.gov/Archives/edgar/data/1625297/000119312526436953/d169609dex991.htm
- https://www.sec.gov/Archives/edgar/data/1356576/000135657626000050/ex991earningsrelease.htm
- https://www.sec.gov/Archives/edgar/data/1625297/000162828026068013/indv-20260930.htm
